Alliance Pharma PLC held its Annual General Meeting, where all resolutions, except for resolutions 16 and 17, were passed. The company's shares in issue at the time of the meeting were 540,565,539 ordinary shares of 1p each. The votes for each resolution were detailed, with the Board noting the votes against certain resolutions and expressing the intention to consult with shareholders to understand their views.

The company's Group General Counsel & Company Secretary, Chris Chrysanthou, provided the breakdown of votes and noted that the Board would consult with shareholders to understand their views and publish the results of that consultation in due course.

Alliance Pharma PLC is a growing consumer healthcare company with the purpose of empowering people to make a positive difference to their health and wellbeing by making trusted and proven brands available worldwide. The company delivers organic growth through investing in priority brands and channels, related innovation, and selective geographic expansion. It also aims to enhance organic growth through selective, complementary acquisitions. The Group employs around 290 people across Europe, North America, and the Asia Pacific region and remains asset-light by outsourcing manufacturing and logistics.

The company's contact information for further inquiries was also provided at the end of the announcement.